1. Valproate but not levetiracetam slows the EEG alpha peak frequency – A pharmaco-EEG study
- Author
-
Johann Philipp Zöllner, Adam Strzelczyk, Felix Rosenow, and Ricardo Kienitz
- Subjects
Adult ,Male ,Levetiracetam ,Adolescent ,Encephalopathy ,Electroencephalography ,050105 experimental psychology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Physiology (medical) ,medicine ,Humans ,0501 psychology and cognitive sciences ,In patient ,Child ,Group level ,Aged ,Retrospective Studies ,Epilepsy ,medicine.diagnostic_test ,business.industry ,Valproic Acid ,05 social sciences ,Brain ,Video EEG monitoring ,Middle Aged ,medicine.disease ,Sensory Systems ,Alpha Rhythm ,Neurology ,Anesthesia ,Anticonvulsants ,Female ,lipids (amino acids, peptides, and proteins) ,Neurology (clinical) ,Pharmaco eeg ,business ,030217 neurology & neurosurgery ,Eeg alpha ,medicine.drug - Abstract
Objective Studies of the effect of valproate (VPA) on the background EEG have shown varying results. Therefore, we compared the effect of VPA and levetiracetam (LEV) on the EEG alpha peak frequency (APF). Methods We retrospectively examined the APF in resting-state EEG of patients undergoing inpatient video-EEG monitoring (VEM) during withdrawal of VPA or LEV. We assessed APF trends by computing linear fits across individual patients’ APF as a function of consecutive days, and correlated the APF and daily antiseizure medication (ASM) doses on a single-patient and group level. Results The APF in the VPA-group significantly increased over days with falling VPA doses (p = 0.005, n = 13), but did not change significantly in the LEV-group (p = 0.47, n = 18). APF correlated negatively with daily ASM doses in the VPA-group (average of r = −0.74 ± 0.12 across patients, p = 0.0039), but not in the LEV-group (average of r = −0.17 ± 0.18 across patients, p = 0.4072). Conclusions Our results suggest that VPA treatment slows the APF. This APF reduction correlates with the daily dose of VPA and is not present in LEV treatment. Significance Our study identifies a VPA-related slowing of the APF even in patients without electroencephalographic or overt clinical signs of encephalopathy.
- Published
- 2021